Clinical Trials
84 trialsTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Kura Oncology, Inc.
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
Spanish Lung Cancer Group
CMML/AML
Kura Oncology, Inc.
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Kura Oncology, Inc.
PTCL
Kura Oncology, Inc.
AIM-HN/SEQ-HN
Kura Oncology, Inc.
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
National Cancer Institute (NCI)
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
Kura Oncology, Inc.
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Kura Oncology, Inc.
Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma
Samsung Medical Center
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
M.D. Anderson Cancer Center
Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
National Cancer Institute (NCI)
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
University of Maryland, Baltimore
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
Lymphoma Study Association
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
National Cancer Institute (NCI)
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia
National Cancer Institute (NCI)
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
SWOG Cancer Research Network
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
University Health Network, Toronto
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
University Health Network, Toronto
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
National Cancer Institute (NCI)
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
National Cancer Institute (NCI)
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Emory University
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
R115777 in Treating Patients With Advanced Bladder Cancer
National Cancer Institute (NCI)
A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
National Cancer Institute (NCI)
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Fox Chase Cancer Center